Literature DB >> 16835779

Void filling of tibia compression fracture zones using a novel resorbable nanocrystalline hydroxyapatite paste in combination with a hydroxyapatite ceramic core: first clinical results.

Franz-Xaver Huber1, Nicholas McArthur, Joachim Hillmeier, Hans Jürgen Kock, Martin Baier, Martin Diwo, Irina Berger, Peter Jürgen Meeder.   

Abstract

INTRODUCTION: It is a generally accepted standard surgical practice to fill-in the metaphyseal defect zones resulting from the reduction of tibia compression fractures. The development of various innovative bone substitutes is also currently on the increase.
MATERIALS AND METHODS: In our prospective study, we used Ostim, a novel resorbable nanocrystalline hydroxyapatite paste, together with Cerabone, a solid hydroxyapatite ceramic, in combination with angularly stable osteosynthesis to treat 24 tibia compression fractures. Types B2 and B3, as well as types C2 and C3 fractures, according to the AO classification, were included in the study.
RESULTS: The mean total range of joint motion in terms of flexion and extension was improved from the immediate postoperative value of 79 +/- 14 degrees to 97 +/- 13 degrees at 6 weeks after surgery, to 109 +/- 16 degrees at 3 months, and finally to 118 +/- 17 degrees at 1 year. In three patients, a delayed wound healing was observed as a local complication.
CONCLUSION: The use of the Ostim and Cerabone combination is an effective method in treating tibia compression fractures with large defect zones left after reduction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835779     DOI: 10.1007/s00402-006-0170-1

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  8 in total

1.  Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects: a randomized controlled clinical study.

Authors:  Bernd Heinz; Adrian Kasaj; Marie Teich; Søren Jepsen
Journal:  Clin Oral Investig       Date:  2009-08-13       Impact factor: 3.573

2.  Human periodontal ligament fibroblasts stimulated by nanocrystalline hydroxyapatite paste or enamel matrix derivative. An in vitro assessment of PDL attachment, migration, and proliferation.

Authors:  Adrian Kasaj; Brita Willershausen; Rüdiger Junker; Stefan-Ioan Stratul; Mirko Schmidt
Journal:  Clin Oral Investig       Date:  2011-06-07       Impact factor: 3.573

3.  Histological evaluation of human intrabony periodontal defects treated with an unsintered nanocrystalline hydroxyapatite paste.

Authors:  Attila Horváth; Andreas Stavropoulos; Péter Windisch; László Lukács; István Gera; Anton Sculean
Journal:  Clin Oral Investig       Date:  2012-05-03       Impact factor: 3.573

4.  Evaluation of a novel nanocrystalline hydroxyapatite paste Ostim in comparison to Alpha-BSM - more bone ingrowth inside the implanted material with Ostim compared to Alpha BSM.

Authors:  Franz-Xaver Huber; Nicholas McArthur; Lydia Heimann; Elvira Dingeldein; Héloïse Cavey; Xavier Palazzi; Gaëlle Clermont; Jean-Pierre Boutrand
Journal:  BMC Musculoskelet Disord       Date:  2009-12-22       Impact factor: 2.362

5.  Nanocrystalline hydroxyapatite for bone repair: an animal study.

Authors:  J Brandt; S Henning; G Michler; W Hein; A Bernstein; M Schulz
Journal:  J Mater Sci Mater Med       Date:  2010-01       Impact factor: 3.896

6.  Major bone defect treatment with an osteoconductive bone substitute.

Authors:  Stefania Paderni; S Terzi; L Amendola
Journal:  Chir Organi Mov       Date:  2009-06-16

7.  A New Injectable Brushite Cement: First Results in Distal Radius and Proximal Tibia Fractures.

Authors:  Christian Ryf; Sabine Goldhahn; Marek Radziejowski; Michael Blauth; Beate Hanson
Journal:  Eur J Trauma Emerg Surg       Date:  2009-05-12       Impact factor: 3.693

8.  Microstructure and biomechanical characteristics of bone substitutes for trauma and orthopaedic surgery.

Authors:  Esther M M Van Lieshout; Gerdine H Van Kralingen; Youssef El-Massoudi; Harrie Weinans; Peter Patka
Journal:  BMC Musculoskelet Disord       Date:  2011-02-02       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.